C4 Therapeutics (CCCC) Expected to Post Quarterly Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) is projected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect C4 Therapeutics to post earnings of ($0.1945) per share and revenue of $8.52 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 12:30 PM ET.

C4 Therapeutics (NASDAQ:CCCC) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. C4 Therapeutics had a negative net margin of 289.44% and a negative return on equity of 45.45%. The firm had revenue of $6.64 million for the quarter, compared to the consensus estimate of $4.00 million. On average, analysts expect C4 Therapeutics to post ($0.81) EPS for the current fiscal year and ($0.95) EPS for the next fiscal year.

C4 Therapeutics Stock Up 5.0%

NASDAQ:CCCC opened at $3.37 on Tuesday. C4 Therapeutics has a 52 week low of $1.69 and a 52 week high of $5.17. The firm has a 50 day moving average of $3.31 and a 200 day moving average of $3.21. The stock has a market capitalization of $414.72 million, a price-to-earnings ratio of -3.38 and a beta of 3.07.

Analyst Upgrades and Downgrades

CCCC has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. started coverage on C4 Therapeutics in a research report on Friday, October 9th. They set an “overweight” rating and a $10.00 price target on the stock. Lake Street Capital began coverage on C4 Therapeutics in a research report on Wednesday, October 28th. They issued a “buy” rating and a $11.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Thursday, October 15th. Finally, Evercore lowered C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.33.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively eliminate disease-causing proteins. The company uses its proprietary TORPEDO platform to design targeted protein degraders, which are intended to direct specific proteins to the cell’s natural disposal system rather than simply blocking their activity.

C4 Therapeutics has concentrated its research and development efforts primarily on oncology, including programs aimed at genetically defined cancers and difficult-to-treat tumors.